← All diseases Rare and hereditary disorders

Hereditary ATTR amyloidosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest quality evidence only (79)Meta-analysis (11)Treatment guideline (1)Phase 3 study (29)Randomized trial (23)Systematic review (15)Clinical trial (345)Review article (146)Early study (phase 1 or 2) (7)Case report (135)Laboratory or animal study (8)Commentary or editorial (72) Studies currently recruiting participants only (34)

Filter

Publications and studies (1285)

• Left atrioventricular coupling index in transthyretin amyloid cardiomyopathy: Association with mortality. (2026/10/15) ♡
• Rate of incident polyneuropathy in patients with transthyretin amyloid cardiomyopathy. (2026/10/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Polyneuropathy in p.V142I hereditary transthyretin amyloidosis: Diagnostic challenges and clinical considerations. (2026/09/15) ♡
• Proteomic profiling of whole tissue sections in cardiac ATTR amyloidosis reveals increased extracellular matrix remodeling. (2026/09/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The presence of transthyretin cardiac amyloidosis in patients undergoing coronary artery bypass graft surgery. (2026/09/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Treatment of transthyretin amyloid cardiomyopathy with tafamidis 61 mg-Real-world data from a tertiary center (TAFA-CRUZ study). (2026/08/05) ♡
• Health Care Resource Utilization in Transthyretin Amyloid Cardiomyopathy Compared With Non-amyloid Heart Failure and the General Population. (2026/08/04) ♡
• Clinical significance of gastric food residue in gastrointestinal hereditary transthyretin amyloidosis. (2026/08/04) ♡
• Quantitative (99m)Tc-PYP SPECT/CT at 90 minutes improves diagnostic stratification in transthyretin cardiac amyloidosis. (2026/08/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Reply to: "A Network Meta-Analysis of Hereditary Transthyretin Amyloidosis With Polyneuropathy Supports a Class Effect, Not a Ranking of Individual Drugs". (2026/08/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Multidimensional care in transthyretin cardiac amyloidosis: Integrating extracardiac organ involvement and comorbidity management. (2026/08/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Systemic light chain and transthyretin amyloidosis-treatment advancements and future directions. (2026/08/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. A Network Meta-Analysis of Hereditary Transthyretin Amyloidosis With Polyneuropathy Supports a Class Effect, Not a Ranking of Individual Drugs. (2026/08/01) ♡
• Sex Differences in Phenotype and Tafamidis-Associated Survival in Val122Ile Transthyretin Cardiac Amyloidosis. (2026/07/25) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: Five-year follow-up of leptomeningeal transthyretin amyloidosis (Ala45Thr) with CNS involvement under tolcapone therapy. (2026/07/22) ♡
• Progressive leptomeningeal involvement on gadolinium-enhanced FLAIR MRI in hereditary transthyretin amyloidosis with the V30M (p.V50M) mutation. (2026/07/17) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Val142Ile ATTR Cardiomyopathy: From Disease Progression to Clinical Stabilization With Vutrisiran. (2026/07/17) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: When peripheral neuropathy meets hoarseness and cough: a diagnostic challenge and insights from a case of late-onset ATTRv. (2026/07/17) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Hereditary Transthyretin Amyloidosis: When Medicine Uncovers a Little-Known Chapter of Canadian History. (2026/07/16) ♡
• Prevalence and attribution of polyneuropathy in p.V142I (V122I) hereditary transthyretin amyloidosis. (2026/07/15) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Disease-Modifying Therapies for Hereditary Transthyretin Amyloidosis with Polyneuropathy: Current Status and Future Perspectives. (2026/07/15) ♡
• Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States. (2026/07/07) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Prognostic impact of chronotropic incompetence in transthyretin cardiac amyloidosis: a multicentre study. (2026/07/04) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Overcoming barriers to early diagnosis and treatment of p.Val142Ile amyloid transthyretin (ATTR) cardiomyopathy. (2026/07/02) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical Outcomes and Health Care Costs in Patients Hospitalized With Heart Failure and Transthyretin Amyloid Cardiomyopathy: Findings From GWTG-HF. (2026/07/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Predictors of poor prognosis in a large cohort of patients with hereditary cardiac transthyretin amyloidosis. (2026/07/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Screening for transthyretin amyloid cardiomyopathy in patients with musculoskeletal symptoms: Red flags in the rheumatology/orthopedics practice setting. (2026/07/01) ♡
• Photon-Counting Computed Tomography for Tissue Characterization in Patients With a Left Ventricular Hypertrophic Phenotype. (2026/07/01) ♡
• Improving transthyretin cardiac amyloidosis detection from electrocardiograms through the Willem artificial intelligence platform. (2026/07/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis. (2026/07/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial. (2026/07/01) ♡
• [Epidemiology and burden on the National Health Service of cardiomyopathy associated with transthyretin amyloidosis based on administrative health data.]. (2026/07/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Awareness, attitudes, and barriers toward Transthyretin Amyloid Cardiomyopathy in Latin America: A questionnaire-based cross-sectional study. (2026/06/26) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Bilateral wrist masses as first manifestation of wild-type transthyretin amyloidosis in a case with recurrent carpal tunnel syndrome: a case report. (2026/06/24) ♡
• Pre-Amyloidosis Red-Flag Clinical Diagnoses in Light Chain (AL) Versus Age-Related Transthyretin (ATTRwt) Amyloidosis: Electronic Health Record-Based Descriptive Study. (2026/06/22) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Synovial Biopsy as a Diagnostic Clue for Transthyretin Amyloidosis With the Rare Tyr98Phe Variant Presenting Predominantly With Severe Musculoskeletal Manifestations. (2026/06/19) ♡
• Factors contributing to the underdiagnosis of hereditary transthyretin amyloidosis (hATTR) in Black patients. (2026/06/17) ♡
• Diagnostic Trends and Geographic Health Care Disparities Among Patients With Transthyretin Amyloid Cardiomyopathy. (2026/06/16) ♡
• Long-term efficacy and safety of vutrisiran in hereditary transthyretin amyloidosis with polyneuropathy: final analysis of the HELIOS-A randomized treatment extension. (2026/06/15) ♡
• Cardiac amyloidosis risk across ethnoracial and clinical subgroups: a five-year national study. (2026/06/15) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Vutrisiran in transthyretin amyloid cardiomyopathy: a structured review of the HELIOS-B trial and its secondary analyses. (2026/06/10) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Transthyretin Amyloidosis-From Peculiar Neuropathy to a Treatable Chronic Multisystemic Disease. (2026/06/10) ♡
• Sensitivity of Nerve and Skin Biopsy and Fat Aspirate for Amyloid in Symptomatic Hereditary ATTR Amyloidosis With Peripheral Neuropathy. (2026/06/09) ♡
• Evaluation of serum neurofilament light chain, GFAP, and peripherin as biomarkers in hereditary transthyretin amyloidosis. (2026/06/08) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Hereditary transthyretin amyloid cardiomyopathy caused by the rare TTR p.Ser43Asn variant in an Asian family: a case report. (2026/06/08) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Therapeutic siRNA: Mechanisms, challenges, strategies, and clinical translation. (2026/06/05) ♡
• Efficacy of diflunisal for hereditary transthyretin amyloidosis: the Swedish real-world experience. (2026/06/03) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Catheter ablation of atrial fibrillation in transthyretin and light-chain cardiac amyloidosis: results from the multicentre AMYL-AF study. (2026/06/02) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Cost analysis of transthyretin amyloid cardiomyopathy in heart failure patients with preserved ejection fraction in Spain. (2026/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The evolving landscape of screening, management and treatment strategies of aortic stenosis in ATTR amyloidosis. (2026/06/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.